Recent Updates
Recently added Catalysts
ANGO Positive Sentiment

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

Friday, October 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AngioDynamics has announced that Jacobi Hospital in Bronx, New York, has been awarded the ALPHA-PE Research Fund. This award supports an independent study led by Dr. Jonathan Alis and Dr. Seth I. Sokol, aimed at advancing real-world evidence for the treatment of pulmonary embolism. The initiative is in collaboration with The PERT Consortium.

Market Sentiment Analysis

POSITIVE FACTORS

  • Jacobi Hospital receives funding for pulmonary embolism research.
  • The study aims to enhance real-world evidence for PE treatment.
  • Collaboration with The PERT Consortium supports innovative research.

Full Press Release Details

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Dr. Jonathan Alis, Dr. Seth I. Sokol and their team at Jacobi Hospital in Bronx, New York have been selected as an ALPHA-PE Research Fund award recipients. The independent, investigator-led study, supported in partnership with The PERT C

Frequently Asked Questions

What is the ALPHA-PE Research Fund?

The ALPHA-PE Research Fund supports independent studies to advance evidence for pulmonary embolism treatment.

Who leads the study at Jacobi Hospital?

The study is led by Dr. Jonathan Alis and Dr. Seth I. Sokol at Jacobi Hospital.

What is the goal of the study funded by AngioDynamics?

The study aims to enhance real-world evidence for the treatment of pulmonary embolism.

Which consortium is partnering with AngioDynamics?

The study is supported in partnership with The PERT Consortium.

ShareAdd on Google
Tags: ANGO AngioDynamics Jacobi Hospital pulmonary embolism research fund The PERT Consortium
Last updated: Oct 2, 2026

Biotech snapshot

Cash runway
$54M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RF ablationPhase 2
Non Small Cell Lung Cancer →